Welcome to the conference call. For the first part of the conference call, the participants will be in listen-only mode. During the question- and- answer session, participants are able to ask questions by dialing star five on their telephone keypad. Now I will hand the conference over to the speakers. Please go ahead.
Good day all, and a warm welcome to Nanoform's third quarter 2026 report presentation. My name is Henri von Haartman, and I am your Director of Investor Relations. Today, our CEO, Edward Hæggström, CFO Albert Hæggström, CCO Christian Jones, and CDO Peter Hänninen will present to you. This presentation is webcasted through Investor Caller, and there is also the possibility to call in and listen by phone. The presentation slides are shown throughout the webcast, and they can also be found on our webpage in the investor section. After the presentation, we will hold a Q&A, and it is possible to ask questions by calling in. We will today start with a short introduction and key highlights, then financials, and after that, we conclude with commercial. With these words, our CEO and founder, Edward Hæggström, please go ahead.
Henri, this is Edward. Can you hear me?
Now I can hear you.
Sorry, I had a technical snafu here. Welcome also on my behalf, and you are looking at the introduction to Nanoform. As we remind you, we offer two technology platforms. We use these platforms to serve global-
Edward, it's Henri here. Listeners, we have Edward in London, and it seems like the connection is quite bad.
Really, our strategies here and vision is that we try to break the wall both for small molecules and for large molecules.
Henri, maybe given the connectivity issues, perhaps Albert could jump in.
Yes, I think actually Edward lost connection there. Albert, are you there?
Yes. I can take-
Okay.
You can hear me well, good. Nanoform, quick introduction. We have proprietary technologies both for the small molecule side and for the large molecule sides. We also have unique knowledge in formulation, and as you remember, we started to work with AI STARMAP many, many years ago, and the idea is there, we can, with AI, see which molecules are amenable to nanoforming. We work with many different kinds of clients, global big ones, mid-sized, and biotechs. We are using the standard industry business model, meaning that there is a combination of service fees, but then we also, as a technology provider, have development and commercial milestones. We can offer on the small molecule side commercial GMP supply, and then of course, as icing on the cake, when products are launched, we expect to receive royalties or profit shares, especially for our kernels.
Our business targets for midterm business targets for 2030, that were launched last December, is for having three Nanoform medicines on the market by 2030, having an income growth above 50% annually during the years 2026 to 2030 on average, and reaching an EBIT margin above 30% by 2030. If you look at the GMP, where we now, of course, came with the big news that we have found a way to elevate the large molecule side to GMP also. As you know, we have built during the last years a state-of-the-art GMP certified facility for the small molecules. We have three manufacturing lines where we have the first one already have commercial license. It has a multi-ton annual capacity, and we can handle highly potent APIs.
Very interestingly enough, we have also been able to scale up the technology, the CESS® technology a lot, and become very cost efficient. We now believe that based on market intel, we are actually a cost leader compared to traditional spray-dried ASDs when we go to commercial scale. We have three small molecule product kernels that are lead ones, enzalutamide, apalutamide, and encorafenib, all the nano versions of them. Peter and Christian will talk more about them. We will also talk more about the big news from a few days back when we signed the global CDMO partner, enabling our large molecule ultra-high concentration to go into GMP, and this is something that the clients have been asking a lot. When can you have GMP for biologics, Nanoform biologics?
We now are very pleased by the fact that together with the large partner, we now have a target of having GMP ready in the second half of next year. The agreement was signed a few days back, and that means that the CDMO partner, which is a global leader in aseptic manufacturing of biologics/large molecules, we will now implement a production line in their facility in Germany, and we are very excited about that because it enables Christian and his team to really tell the clients that, "Hey, now you have worked with us on R&D side on the biologics. Now we can actually take you to clinic together with our partner and his facility in Germany." If we then go over to the financials, here you can see the number of projects signed.
Remember that summer months are usually a little bit slower, both on the signed projects and on the revenue, because when you are a holiday, you don't book revenue. But here you can see that we signed one more non-GMP project than last year in the third quarter, and that took the trailing 12 months up to one more than in the previous quarter. You can also see that the proportion of GMP projects is increasing, and that is something we have been targeting for the last 12 months now that we take slightly fewer high-risk projects as non-GMP. We focus more on taking projects where we can get a higher probability of them moving to GMP.
It's also a clear situational change that in the beginning, we got lots of test molecules, and now when the clients have tested us, we have much more data and they know what we can do. Now they bring us more live projects, meaning that the likelihood of them going to GMP is higher. If we look at the income side, we had strong growth in the revenue and the continued growth in the total income, and the gross margin was almost 90%, which is our target. On the operating expenses, you can see that they have come down a lot. They were down 35% in the first nine months. Actually, they were, of course, down more in the third quarter.
They were down 40% in the third quarter, so there was a big improvement in the EBITDA both in the first nine months, but especially also in the third quarter. Remember that when we think about the next year and what kind of revenue do we need to start to get into a situation where we come closer to break-even, remember that the first quarter of this year, we still had a lot of full force from the phase where we were building the factory, and now it has come down a lot. So next year will be easier from a comparison point of view on the cost side. If we look at our near-term business targets, they are unchanged. Cash burn below EUR 10 million. We believe we have a fair chance of achieving that.
We plan imminently to file the first marketing authorization application for a Nanoform medicine, and that would be in the U.K. And for somebody who asks, "What does imminent mean?" We think of it as weeks. We are targeting an increased number of non-GMP and GMP projects signed this year. We were up one versus last year after nine months, and then we are working hard on the last one, which is to sign development and license and commercial supply agreements on several kernels during this year. Our 2030 business targets are unchanged. As I said, three products launched, 50% annual average growth over the five-year period, and by doing that, we should be able to have an EBIT margin above 30%. And with that, I hand over to Christian. Please go ahead.
Thank you, Albert. Pleasure to take you through our commercial update. Just to recap on our value proposition, we have two proprietary platforms. In small molecules, it is about making smaller particles and better medicines, creating nanometer-scale particles that can have really improvements in the bioavailability, but also in making fewer smaller tablets and reducing that pill burden. It is a simple and it is a green and it is a scalable technology, and now it is a cost-competitive technology to spray-dried solid dispersions. And we are able to scale up to 10 tons at the moment within our capacity from Nanoform facility in Finland. And we have a clinical and a GMP commercial license. On the large molecule side, it is about taking products that are IV-delivered currently and transitioning them to subcutaneous drug delivery. We do this by creating nanoparticles as small as 50 nm.
creating ultra-high concentration suspensions, greater than 500 mg/ mL, and making stable formulations without potentially the need for cold chain and enabling new delivery routes. Of course, our biologics technology also has other applicational areas, but this is the main focus for the technology. And by partnering with clients in biotech and pharma, by using IP-protected technologies, we can add further value to their products, and we look to receive upfront fees, milestones, and royalties for the value that we create. So, we are providing a lot more value than a typical CDMO. So, small is powerful, and we are here to make better medicines.
To recap or to cover the commercial highlights for this quarter, clearly the standout highlight is the agreement we have just signed with a global CDMO around our ultra-high concentration large molecule technology, with a targeted readiness for GMP supply for our first client during the second half of 2027. This is by far an enabler for Nanoform. We have generated significant R&D interest with our clients, both in U.S., Europe, and Asia, around our technology. Now we provide a critical pathway to GMP, which is essential, in fact, for doing commercial deals with these partners as well. Then we talk about our product kernels, and I will not talk too much about this because Peter will cover it in more detail. But nanoenzalutamide is our first, and here we have a multi-track strategy for submission, regulatory submission to different regulatory bodies.
As Albert mentioned, our first marketing authorization application in the U.K. is imminent, and lots of interaction with other regulatory bodies as we speak. GLIORA is a project that we have been working on that is focused on brain tumors, and here we are combining APIs, nano-APIs in a hydrogel formulation. We got some very positive feedback from the FDA recently, and this is fantastic because it reduces the regulatory complexity and strengthens the program's partnering potential. Another client of ours, PlusVitech, developing a molecule for lung cancer, they have now recruited the first patient in their phase I/II clinical trial for repurposing aprepitant. This is great news. It really supports them as a business and will give confidence to moving forward with a nano-formulation very soon. I also wanted to mention recent publication with Takeda. This information is not new news. We have talked about this last year.
This is work done with Takeda around respiratory drug delivery of alpha-1 antitrypsin, but it is the first time for Nanoform that we have had our work published with a major pharmaceutical company in a high-impact journal, and we are very proud of that, and we will talk about that more later. Just overall, the number of regulatory interactions, including with the FDA, across both our small molecule and large molecule products have really increased. So it is a very, very busy time for Nanoform, and we are very pleased to see the commercial and regulatory traction that we are seeing. If I talk a little bit about the Takeda work. So what did we do here? We took Takeda, as you know, have a large plasma-based therapy area, and within that, alpha-1 antitrypsin is currently given to patients. Aralast is the product that is given IV to the patients.
It is for lung disease, and typically, a large proportion of that, 98%, stays in the blood, with only a very, very minute amount actually getting to the lungs. The idea here was, well, by nanoforming, by creating dry particles, could they be delivered in a dry powder inhaler? We did an animal study where we did this work with them. We saw that actually 95% was retained in the lung and only 5% went into the blood. So this was a really, really strong result and something they were very excited about, and we are also very pleased about. Using other techniques to dry proteins and particles like this is possible, but of course, spray drying can denature some biologics. In this example, they also tried spray drying, but they were only able to get a very small proportion of the drug into the lungs versus the nanoforming capability.
Very great results there. If we go back a few weeks, we were at the PODD Conference, which really is a keystone event in the calendar for drug delivery. I would say the level of interaction is really C-level to SVP around business development and licensing within drug delivery. Here Nanoform presented. We presented some of our data, but we also were presented about by PharmaCircle. PharmaCircle is a business intelligence platform. Each year at the PODD event, they give a keynote talk on the drug delivery landscape. Kurt Sedo from PharmaCircle presented, and in this talk, he focused in on the IV SubQ space. Who are the leading technologies? Here you see Halozyme, Alteogen mentioned for the hyaluronidase approach, closely followed by Nanoform biologics platform.
We were delighted to be center stage at this event in front of an audience of over 1,000 people. If we move forward to the next slide, our work continues in many different ways. We work with our clients. We also work to better understand how our products can be administered, and we've done work with prefilled syringes in the biologic space. They work very well. We started to look at different devices. Midas and Gerresheimer visited our facilities in Finland and brought in one of their autoinjector devices, the Gx Inbeneo. We were able to test that device with our formulation, and we got some great results. With a high concentration suspension, we were able to achieve more than a gram of mAb delivered in less than 15 seconds.
We're really excited about the potential to apply ultra-high concentration suspensions with devices as well to enable higher drug dosages that wouldn't be possible without. Now I'm going to hand over to Peter to take us to the next slide.
Thanks, Christian. I will start by reiterating that we expect that the U.K. filing is imminent for nanoenzalutamide, and this is, of course, as was said by Albert, in line with our target to submit a first marketing authorization application for a Nanoform medicine still this side of the year. In addition to that, we've, of course, also continued the disciplined execution on the rest of the kernel pipeline and have chosen to deprioritize two early preclinical programs there, one an oral solid dosage form and the other the inhaled semaglutide project. That's really just because we see so much more opportunities in the rest of the pipeline that we want to focus our limited resources on those programs. From these other programs, we're working towards getting now both Nanoapalutamide and Nanoencorafenib into a pilot human study as a next step.
And, of course, as was said, we were very, very happy with the response we received from the FDA on our development plans for GLIORA. As a reminder, GLIORA is a joint development we have with Revio Therapeutics, where we are combining Nanoformed olaparib and temozolomide in a locally administered long-acting hydrogel for high-grade gliomas. The aim here is to improve the efficacy and tolerability through sustained drug delivery directly to the tumor resection cavity. The feedback we received from a Type C meeting with the FDA, that actually came ahead of schedule, supports the proposed CMC preclinical and clinical development strategy for this product. I think important to hear the FDA confirmed that GLIORA will be regulated as a standard drug-drug combination with the polymer that treated as an excipient.
I think overall, the feedback will reduce the regulatory complexity and support our partnering and out-licensing discussions. I think across both us and Revio, as well as a number of partners that we are talking to, we are all very, very excited about this product. This is, of course, an area where there is a high unmet need, and we believe this can really be a terrific development program for us. We were also pleased to hear from PlusVitech, where we hold a 9% ownership share, that they have now recruited the first patient in their clinical study that assesses aprepitant for a new indication.
The study that now is ongoing uses the currently available commercial formulation, but in parallel, and what our role is that we are working with PlusVitech on a reformulation to significantly reduce pill burden, which with the current commercially available formulation would require several tens of capsules per day to be taken by these oncology patients. Turning over to biologics, which is, of course, obvious, but I say it anyways, we see a large market forming in subcutaneous delivery of monoclonal antibodies, and we are very confident that this will be a continuing theme over the coming years. There are three points on this slide. First, we believe subcutaneous delivery will become the dominant standard for new and marketed biologics.
Second, to enable that shift at scale from IV to SubQ, suspension formulations are important because they can enable high concentration levels, which in turn means lower injection volumes. Lower injection volumes can avoid these complex formulations and devices you see with some of the current marketed SubQ products for higher dose antibodies. Because particle properties matter so much for the performance of these, we are very confident, based on what we have seen so far, that our technology can become a technology of choice in enabling subcutaneous delivery via suspensions. Of course, in order to enable this, we need to get to clinic. Just before summer, we shared the news that we have signed the first exclusivity deal for our technology and that we are looking to progress it towards clinic without delay.
We've now, as of the news we set out this week, taken an important step towards that goal with the agreement we had with the CDMO, and can say with confidence that we are targeting a GMP readiness for the second half of 2027. There is an established market and business model for drug delivery technologies that can enable SubQ delivery for biologics. The slide here really highlights why there are so many product developers in this space that are actively looking for alternatives. For each target, there will always be a certain number of competitors who need to find an alternative enabling technology due to the exclusivity deals that Halozyme and the others have been making in this space.
For ultra-concentration SubQ delivery specifically, we're very confident that we have an opportunity here to be one of the first to reach clinic, to be first, and then to continue to strengthen our position as a leader in this sector. I would highlight this, that was on actually one of the slides Christian spoke to, that all of the other particle-based delivery technologies on the slide are labeled as preclinical. So we very much look forward in the next board to maybe have already changed that label when it comes to our platform. With that, I thank you and turn it over to Henri.
Thank you, Peter.
If you wish to ask a question, please dial star five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial star five again on your telephone keypad. The next question comes from Christian Glennie from Stifel. Please go ahead.
Hi. Good morning, chaps. I guess firstly on the CDMO, and congratulations on that agreement. I guess can see very clear logic, strategic rationale from your perspective, but I guess an interesting way to sort of flip it around maybe, what do you think the CDMO partner sees particularly in the technology, and what was sort of involved, I guess, in presumably quite an extensive DD process on their side, and to what extent did that maybe involve the U.S. biotech company that obviously potentially is that target first molecule into clinic? Thank you.
Christian and Peter, if you want to comment on what they see, why do they want to do a deal like this with us?
Yeah. Thanks, Albert. Happy to take a stab at that first and then hand it over to Christian. I think first, they see the same market dynamic that we are seeing, that going forward, the delivery of biologics will not be so dominated by IV formulations as so far, because IV has really been a necessity due to the lack of technology choices available, and not something that would have been preferred from a patient or treatment perspective. So they see that change happening, and they want to be a part of it.
There's a limited number of technologies available in that space, and I think, I mean, we've been working with them now very, very closely on this for the good part of this year, and with visits back and forth, and I think they see that we have a clever, scalable, robust technology that is well-suited for clinical, but ultimately commercial manufacturing, and that's the business they are in. So, I think that's where ultimately they want to service clients and get paid for that service, and they see this is a great opportunity to build their own business. But maybe turning it over to Christian for his thoughts.
Sure. Thanks, Peter. I would just add, they are obviously a major player in the biologic space. They will have significant amounts of their business and revenues coming from manufacturing of drug product in IV formulations. But they also see that the market is potentially changing, and that there is going to be a move towards more SubQ drug delivery, and that this ultra-high concentration space is potentially going to become a big part of the future. They want to have a stake in that, and they believe that Nanoform's technology is potentially going to be a real leader in that field. That is what I would say to that, Christian.
I would add to that when we announced the agreement with the U.S. customer, some people said to us that, "Why would any CDMO be interested in letting you put a line in their facility?" Lots of people, of course, have lots of opinions, and it is never easy to estimate before you start negotiations to really do it. But we have been very positively surprised by the fact that the interest from different CDMOs to do a deal with us, where we put our line into their facility, has been very good. As we said in the previous report, we were having concrete offers from several reputable ones, and now we have chosen the one where we felt that it was really, really a perfect fit between us.
All these three parties, us, the CDMO, but also the clients, we all felt that this is a very good fit. They have a slightly different business model than us. They think very much about the commercial state, the end state. We love that, because that means that the client also can see the road all the way to commercial, not only for the development, but also the fact that they are focusing on the sort of, they have a business model where they focus on fee for service, while our focus is more on milestones and royalties in the long run, because we will not have the, at least initially, the sort of the GMP in our facility.
This was really a win-win, and the fact that we were able When we, a year ago, were thinking about, "Can we build it in Helsinki?" Our estimates were that it could cost EUR 20 million-EUR 30 million, something like that, and it would take us two, three years if you are a little bit conservative, and we do not have long knowledge or knowledge of aseptic manufacturing. Now we get a partner that has a very good long track record in aseptic manufacturing. They have the facility ready. We just put our line there. The [CapExes] are a fraction of what they would have been if we would have done it as a greenfield. Because we have so different business models, that was also very sort of, in a sense, surprisingly easy discussion.
I would rate this sort of fit between us, but also for the client, the customer, this makes their timeline better. They can get GMP material, the batch to clinic, much faster than they would have done otherwise. We are really, really positive about this recently signed agreement.
Thanks. That is clear. Then I guess the sort of follow-on to that inevitably is, the potential license that you have got with your U.S. client, it seemed to be obviously the trigger for that progressing to a more formal license, was obviously related to the sort of capabilities around GMP. Is that something that potentially just by virtue of having this agreement in place, is something that can then advance fairly near term? Or perhaps does it have to wait for that, I guess, that final confirmation of a fully functioning GMP line using your technology before that becomes a formal license? Just a sense for that.
If I start and then let Peter continue. I start like this, that one of the reasons we also like the partners that we now have is that they have the same sense of. Also, we feel that they have the same sense that it is important to have a speedy process, speedy high-quality process, because as we all know, if you are one year slow in the early stages of a development, R&D, or early clinical, that can mean EUR 1 billion or several billions of lost revenue 10 years later. This is one of these where we really like the partners we are involved with here, because we all share this sense of urgency that you cannot be slow just because it is early days. You need to always keep the momentum.
I would say that we are positive that we can come to some sort of final agreement rather earlier than later. But Peter, would you like to comment a little bit more?
I think what we said in May still holds in a sense that they paid what you could call a sort of reservation fee in a sense, to allow time to gain line of sight to GMP manufacturing and entry into clinic with our technology. Now we have that. We expect things to progress from here as we've earlier communicated.
Thank you. Maybe one final one if I can, please, just on nanoenzalutamide. Specifically, obviously, you sound like filing imminent in the U.K. A rough estimate for potential sort of review timelines from there, and then just the sort of status you talk about still doing some of the work on the Cmax side of things. What's the potential timings around, I guess, some conclusion of that work that you're pursuing as well?
Yeah, sure. If I start by saying that this is, of course, Nanoform is not the one who is submitting the application. It's our partner or partners. We are part of that application with our part from the technology side. The timelines are the normal U.K. timelines, so you can sort of look up that. When it comes to the difference between the different pathways, we were of course positive by what we got from the advice meeting in August and the hybrid pathway. Related to the other areas, we are now waiting for, let's say, feedback from different countries, from the U.S. FDA, from different countries in Europe related to the hybrid pathway after the change to the sort of the regulatory landscape, if you would call it like that, or the new stuff that came out.
We will be telling you more in the coming months related to the different areas. At this moment, we are focusing on the fact that the timeline for submitting the application for U.K. is imminent, and that means that we would hit our target for having the first one during 2026. Peter or Christian, is something you want to add?
Not from my side, no.
Okay. Thank you. That is clear.
The next question comes from Christopher from SEB. Please go ahead.
Hi there, Christopher Uhde, SEB. Thanks for taking my question. Just one housekeeping question, please. Can you tell us how you have been recognizing the revenue from the retainer fee for the U.S. biotech and when do you expect it to be fully recognized? Thanks.
Yeah, sure. So it is, as we said previously, we recognize it 12 months over a one-year period, and it is linear. So you take the $1 million and you convert it to EUR and you divide it by 12, then you get per month, and then you take it times three, you get the third quarter part of it. That will continue until it is the 12 months since the signatures have gone.
Thank you.
The next question comes from Sami Sarkamies from Danske Bank Markets. Please go ahead.
Hi, I have a couple of questions, starting from the CDMO deal. Firstly, how should we think about operating expenses following this deal? I guess you need to, for example, relocate some staff to Germany.
We will have some staff traveling there when they take transfer the line and implement it together with the CDMO staff. But once it is up and running, we will not have permanent staff there. It will be under responsibility and under the supervision and within the QMS system of the CDMO. We will not have permanent staff in Germany.
Okay. Can you somehow elaborate on the commercial agreement between you and the CDMO? Are you going to be paying upfronts? Will there be retainers? What will be their share of royalties ultimately?
What I have been saying is, trying to indicate is that we have quite different business models where we focus on the milestones and the royalties in the long run, and they have a classical CDMO business model of fee-for-service. When the project comes to All projects starts at Nanoform, and then we do our normal PoCs and PoPs and the tech transfers. When it goes to the CDMO, they, of course, then have a contract with the end clients, where the end clients pay them for the clinical batches or vials or whatever they need. Related to the contract or agreement between us and CDMO, we will not disclose any details.
Okay. Then finally, regarding the CDMO deal, how should we think about your revenues related to the current agreement with the U.S. biotech company? How could they, in a way, ramp up and progress following the GMP manufacturing has now been sorted out?
What we said in the one press release was that we, of course, have an exclusivity arrangement or agreement with the end customer, and that is the business model for us. We will sign up the customers with the exclusivity agreements, and that is separate from any other agreements we have with the CDMO. What we said then was that the total potential milestones could be high tens of millions over the total period for development milestones and regulatory milestones and sales milestones, and then with the low to mid-single digit tiered royalty.
Okay. Then moving on, just curious regarding the overall commercial momentum you are seeing at the moment. Do you see possibilities for more deals with, let us say, listed customers related to small and large molecules over the next six months?
Christian, do you want to take this question?
Yeah.
How do you see the commercial momentum?
Yeah, absolutely. Thanks, Sami. Yes, I do see that there is an increase in momentum, particularly around the biologics, but also in the small molecule space. I would say in the next six months, I'd be very hopeful that we have further deals like the ones that we've been talking about today.
Okay. Finally, I think you said that you will be making progress towards cash flow breakeven during next year. Just wanted to check, did you actually mean that you could be reaching a breakeven point during next year, or was just the idea that you will be making further progress during next year?
We will, of course, come out with targets for next year when we report the next time, the full year. What I was saying that we will continue to make progress towards that. I did not say that we would reach it next year, but the official target will come when we report the full year numbers.
Okay, thanks. I don't have any further questions.
There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Edward, are you there?
I'm online, yes.
Do you want to say a few words?
Absolutely delighted, and first apologies for not being able to come in. The network here in London is apparently not superb. What you have seen is the depth of our bench. The management team members were able to carry the conference, even if I was sitting in the listening chair. I think that is very important to make a note of. Then I would like to remind all of us from the first slides that we are now having two tech platforms that are soon to be on GMP level. That means two S-curves to ride. It is also important to remember that we now have a small molecule facility that is preparing to launch [inaudible]. We will be launch-ready internally next year, and we will also be starting to make Nanoform material for the commercial launch at the end of next year.
This is one important milestone on a long journey. Today, we have talked a lot about the large molecules, and that is, of course, maybe the number one news this week. But it is very important to understand the small molecule leg and the large molecule leg now are starting to be equally strong, and they are strong. It was also mentioned the increasing volume of interaction with the regulatory bodies globally. This here is something which we are going to talk more and more about, because it is going to have a lot of impact into what we do. So, on my behalf, thank you very much, and apologies.
Thank you, Edward, for that. On behalf of Nanoform, I would like to thank all participants for today. If you have more questions, then please do reach out to us, and we wish everybody a great Thursday afternoon and evening. Thank you and goodbye.